🌍 From Switzerland to the World: CSL Behring’s Apprenticeships at https://bit.ly/4gZxtqc 2024 🚀 At CSL, we’re committed to developing the next generation of skilled professionals across the globe. This year, our team in Switzerland proudly participated in https://bit.ly/4gZxtqc 2024, the largest vocational fair in the Bern region. With over 22,000 visitors exploring 22 career fields, the event provided young people a chance to discover exciting opportunities in industries like manufacturing, research, logistics, and administration. Our participation wasn’t just about showcasing CSL Behring’s local apprenticeship programs—it’s part of our global mission to engage with future talent. Whether in laboratory sciences, technical fields, or business-related roles, we’re equipping apprentices with the skills to succeed in Switzerland and across CSL’s global network. https://bit.ly/3zQsNlD #CSL #CSLBehring #GlobalTalent #Apprenticeships #Innovation #BAM2024 #FutureLeaders #TalentDevelopment #VocationalTraining #PromisingFutures
International Plasma Awareness Week: Every Donation Makes a Difference
International Plasma Awareness Week is 7-11 October, and celebrates the incredible impact donating plasma creates.
We have released our 2024 Annual Report Click here to read the Annual Report → | We have announced our 2024 Full Year Financial Results for the period ending June 30th 2024. Click here to view Information and Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: CSL employees in Melbourne, Australia
At CSL, innovation isn’t just encouraged – it’s celebrated. Our employees thrive in an environment where they feel empowered to solve problems creatively, experiment fearlessly, and learn from every challenge. #PromisingFutures #CSL Ready to make your mark? Join CSL today: Explore Careers https://bit.ly/3XVZUML
The CSL Behring Broadmeadows leadership team recently volunteered at Foodbank Victoria, packing the equivalent of 31,410 meals for Victorians doing it tough. Through CSL’s support, Foodbank is helping feed 65,000 people a day - another example of our people helping to give back to the communities where we work. https://bit.ly/4dAvG83 #CSL
This past weekend, our team had the privilege of participating in the annual Riding for a Reason Escape to the Cape Alpha-1 event in Cape Cod, MA. Organized by the American Lung Association and the Alpha-1 Foundation, this event was a powerful gathering of the Alpha 1 community, featuring a scenic 50 or 100-mile bike ride along the stunning coast and dunes of Cape Cod. Our employees were deeply moved by the stories of resiliency and hope shared by patients, families and caregivers. The sense of community and support was truly inspiring. We are incredibly proud of our team for their dedication and enthusiasm, and we extend our heartfelt thanks to everyone who participated and supported this cause. Together, we are making a meaningful impact and moving towards a brighter future for the Alpha 1 community. #Alpha1Awareness #DrivenByOurPromise
At CSL, excellence is our standard in every aspect, especially in Manufacturing and Supply Chain operations. Our dedicated employees ensure top-quality products and optimized distribution networks, playing a vital role in delivering lifesaving therapies to patients around the globe. #PromisingFutures #CSL Looking to elevate your career? Discover exciting opportunities and join us in making a real difference. https://bit.ly/3NcmwDM
Buzzing with excitement! OPTIONS XII is underway in Brisbane, Australia. Our #CSLSeqirus colleagues are on the ground sharing the latest groundbreaking data, including real-world evidence, and insights with the global influenza community through dynamic oral presentations, poster sessions and symposia. We’re also proudly showcasing our rich public health legacy in Australia, our cutting-edge expertise in seasonal and pandemic influenza responses and our ambition to improve global outcomes. #PublicHealth #Vaccines #Influenza #OPTIONSXII #OPTIONS2024 #Brisbane #Australia #CSL #DrivenByOurPriomise
As #SickleCellAwarenessMonth comes to an end, CSL remains committed to helping those with sickle cell disease better manage their health through ongoing research and solutions. Read more here: https://bit.ly/3Xx0pgl.
Today marks 15 years since the rollout of Australia’s 2009 Swine Flu vaccination program. Vaccines manufactured at CSL’s Melbourne, Australia facility were TGA-approved 99 days after the pandemic was declared by the World Health Organization. During the 2009 pandemic, our expert employees helped develop, manufacture, assess, and distribute over 21 million doses to help protect Australians. CSL Seqirus is committed to pandemic preparedness and rapid response and is a proud partner to over 30 governments worldwide. Learn more about how we continue to help governments prepare for future influenza pandemics: https://bit.ly/3N6JvQU #CSL #CSLSeqirus #PublicHealth #Vaccines #InfluenzaPandemic
🌍Global Collaboration at CSL Melbourne!🌍 We were thrilled to host international influenza experts and public health partners at CSL Melbourne for the recent World Health Organization Southern Hemisphere Influenza Strain Announcement. These bi-annual announcements are crucial as they analyze global data to recommend the flu strains for the upcoming season’s vaccines. This event also marks the kick-off of Southern Hemisphere operations for #CSLSeqirus Learn more our role in helping to protect Public health: https://bit.ly/3zNi1fM #DrivenByOurPromise #CSL #Melbourne #WHO #Australia #PublicHealth
We're delighted to be welcoming the world’s influenza community to Australia next week for OPTIONS XII for the Control of Influenza – the only global scientific meeting with a dedicated focus on influenza. OPTIONS provides #CSLSeqirus with a unique opportunity to share our latest data, including real-world evidence, and insights with the global community. Read our official opening letter from Dave Ross, Senior Vice President and General Manager – CSL Seqirus: https://bit.ly/3N35ckO #CSL #DrivenByOurPromise #Brisbane #Australia #PublicHealth #Vaccines #Influenza #OPTIONSXII #OPTIONS2024
